Jazz Pharmaceuticals Hits New 52-Week High of USD 255.05

Jazz Pharmaceuticals Plc has reached a significant milestone by hitting a new 52-week high of USD 255.05 on July 21, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable one-year performance of 133.25%, significantly outpacing the S&P 500's 19.09% return. With a market capitalization of USD 11,246 million, Jazz Pharmaceuticals has shown impressive financial metrics, including a price-to-earnings (P/E) ratio of 18.00 and a return on equity of 14.85%. The company has consistently reported positive results, with net profit for the latest quarter reaching USD 301.43 million, reflecting a staggering growth of 398.01%. Additionally, the inventory turnover ratio stands at a high of 2.59 times, indicating efficient management of inventory. The stock's performance is further bolstered by a healthy long-term growth trajectory, with net sales increasing at an annual rate of 12.54%. With high institutional holdings at 100%, Jazz Pharmaceuticals continues to solidify its position as a reliable performer in the market.